6506 Background: IM was proven to be superior to IFN+ Ara-C for newly diagnosed patients
(pts) with CML-CP (O'Brien et al, NEJM 2003). 1,106 pts were randomized between June …

Abstract The development of Bcr‐Abl tyrosine kinase inhibitors has dramatically changed
the prognosis of patients with newly diagnosed chronic myeloid leukemia (CML). Standard …

The advent of tyrosine kinase inhibitors (TKIs) has drastically changed the treatment
outcome of chronic myeloid leukemia (CML). Imatinib was the first TKI approved, and has …

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm and was the first
neoplastic disease associated with a well-defined genotypic anomaly―the presence of the …

The initial treatment for chronic myeloid leukemia in chronic phase (CP‐CML) represents a
complex process, which includes a prompt and precise diagnosis, the choice among three …

Several guidelines and recommendations on the management of chronic myeloid leukemia
(CML) have been prepared by several scientific societies. The European LeukemiaNet …

Management of chronic myeloid leukaemia (CML) has recently undergone dramatic
changes, prompting the European LeukemiaNet (ELN) to issue recommendations in 2013; …

Abstract Abstract 207 Background: Results from the phase 3, international, randomized
ENESTnd trial have demonstrated the superior efficacy of nilotinib over imatinib with …

Chronic myeloid leukemia (CML) is a progressive and often fatal myeloproliferative
neoplasm. The hallmark of CML is an acquired chromosomal translocation known as the …

Chronic myeloid leukemia (CML) results from the clonal expansion of pluripotent
hematopoietic stem cells containing the active BCR/ABL fusion gene produced by a …